Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Jack Satsangi

Lee Placito Professor of Gastroenterology

Lee Placito Professor of Gastroenterology

Jack Satsangi is the  Lee Placito Professor of Gastroenterology,  University of Oxford; a Governing Body Fellow at Green Templeton College;   and an Honorary Consultant Physician in Oxford University Hospital NHS Trust.  He qualified in Medicine from St Thomas’s Hospital Medical School, London in 1987; and he completed his postgraduate training in clinical and academic medicine in Oxford  as an MRC Fellow and Clinician Scientist, working with Derek Jewell and John Bell. He completed his DPhil in 1996 on the genetics of inflammatory bowel disease.

 In 2000,  Jack succeeded the late  Anne Ferguson as Professor of Gastroenterology in Edinburgh, with the intention of building  on her legacy to develop a centre of excellence in inflammatory bowel disease. He returned to Oxford to take up his present post in 2018. He continues to hold an honorary chair in the University of Edinburgh.

 Jack has combined  care of patients with Crohn’s disease and ulcerative colitis with  basic, clinical and translational research; and post-graduate and undergraduate teaching.  His areas of clinical interest have centred on complex and challenging  IBD –  and have included the management of severe colitis; the management of childhood-onset disease; the safety and efficacy of biological agents, and of novel therapeutic approaches; and the introduction of personalised medicine into clinical practice.

 He has been involved in a number of important research advances and publications,  including the discovery of cytokine dysregulation in IBD;  the  definition of the genetic architecture of inflammatory bowel disease; the re-classification by phenotype of inflammatory bowel disease;  investigation of gene-environmental interactions; disease epigenetics, and multi-omic analyses in biomarker discovery. He  currently is Chief  Investigator of the global ICARUS – IBD consortium assessing Covid-19 impact in IBD, led from Oxford and New York; and he leads a number of other initiatives in personalising care, and treatment options.

 His current research interests are translational. Laboratory studies are  centred on the personalisation of care in inflammatory bowel disease, with a focus on the application of multi-omic technologies in the   definition of phenotype, disease progression and drug response. Epigenomic analysis in both children and adults is a key area of interest. Clinical studies focus on the de-escalation of biological therapy; the response to Covid19 and vaccination in patients with inflammatory bowel disease; the development of predictive indices in severe colitis; and the development of non-immunogenic anti-TNF therapy.

 Jack has been Secretary of the BSG IBD Committee, and was the first Chair of the BSG IBD Research Committee. He has led National and Regional NIHR Speciality Groups in Gastroenterology; as well as a co-ordinating a series of international research consortia supported by the European Community, and Helmsley Trust. He  represents  the Royal College of Physicians on the Board of the UK IBD Registry. He has supervised a series of research-active clinicians and students  in UK  and Europe. He is a Fellow of the Academy of Medical Sciences and of the Royal Society of Edinburgh.

 Jack has been a Medical Advisor to the Crohn’s Colitis UK Charity for over 20 years; and has acted as a Trustee or Committee member to CICRA  and CORE/GUTS-UK. He has led a series of recent initiatives in increasing Patient and Public understanding of research, in respect to Covid-19 as well as new therapeutic options.